Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Ocular implant made by a double extrusion process|
|Abstract:||The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.|
|Inventor(s):||Shiah; Jane-Guo (Irvine, CA), Bhagat; Rahul (Irvine, CA), Blanda; Wendy M. (Tustin, CA), Nivaggioli; Thierry (Atherton, CA), Peng; Lin (South San Francisco, CA), Chou; David (Palo Alto, CA), Weber; David A. (Danville, CA)|
|Assignee:||Allergan, Inc. (Irvine, CA)|
|Filing Date:||Sep 01, 2011|
|Claims:||1. A method for making an ocular bioerodible implant for treating a medical condition of the eye, the method comprising: a) milling a hydrophilic ended poly(D,L-lactide-co-glycolide) (PLGA) polymer; b) milling a hydrophobic ended poly(D,L-lactide-co-glycolide) (PLGA) polymer; c) blending the milled polymers together with particles of dexamethasone to form a blended mixture comprising a hydrophilic ended PLGA, a hydrophobic ended PLGA, and dexamethasone, wherein at least about 75% of the particles of the dexamethasone have a diameter of less than about 20 .mu.m; d) performing a plurality of heat extrusions of the blended mixture, thereby forming a filament including a homogenous distribution of the dexamethasone, wherein the ocular bioerodible implant has a reduced in-batch variability relative to a single extrusion implant. |
2. The method of claim 1, wherein the bioerodible implant is sized for implantation in the vitreous cavity.
3. The method of claim 2, wherein the dexamethasone constitutes from about 10% to about 90% by weight of the implant.
4. The method of claim 3, wherein the dexamethasone constitutes from about 40% to about 80% by weight of the implant.
5. The method of claim 4, wherein the dexamethasone constitutes about 60% by weight of the implant.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.